PROGRAM MENU
Educational Program

THSNA programming is focused on presenting the most current issues in Hemostasis and Thrombosis. THSNA 2020 will include daily plenary sessions (without other concurrent sessions); four educational tracks, a Pre-Summit Workshop Day, daily ePoster sessions, oral abstract presentations of original research and an exhibit hall with commercial booths.


  Wed - Apr 22      Thu - Apr 23      Fri - Apr 24      Sat - Apr 25   

FRIDAY, APRIL 24

7:00 - 7:45 AM
SATELLITE SYMPOSIUM
JANSSEN CORPORATE BREAKFAST
Chicago Ballroom 7


SANOFI GENZYME CORPORATE BREAKFAST
Chicago Ballroom 6

8:00 - 9:00 AM
BASIC SCIENCE
NEW INSIGHTS ON MECHANISMS
Chair/Organizer: Shannon Meeks , Rodney Camire
Chicago Ballroom 10


8:00
28

ADVANCES IN UNDERSTANDING THE COFACTOR FUNCTIONS OF FACTOR V AND FACTOR VIII
Rodney Camire. University of Pennsylvania/Children's Hospital of Philadelphia


8:20
29

UNDERSTANDING THE CLOT FROM STUDIES OF FIBRIN AND FACTOR XIII
JW Weisel. University of Pennsylvania


8:40
30

UPDATE ON THE INTERPLAY BETWEEN COAGULATION AND COMPLEMENT SYSTEMS
Edward Conway. University of British Columbia Centre for Blood Research

8:00 - 9:00 AM
HEMOSTASIS
NEW STRATEGIES IN HEMOPHILIA THERAPY
Chair/Organizer: Kathleen Van Gordon, Christine Sabapathy
Sheraton Ballroom 5


8:00
25

CHALLENGING BLEEDING EVENTS IN PATIENTS ON NOVEL HEMOPHILIA THERAPIES
Glaivy Batsuli.


8:20
26

TOLERANCE IN THE AGE OF NON-FACTOR REPLACEMENT THERAPY
Shannon Meeks. Emory University/Children's Healthcare of Atlanta


8:40
27

HOW NEW THERAPIES ARE IMPACTING HEMOPHILIA TREATMENT CENTERS
Jim Munn. Michigan Medicine

8:00 - 9:00 AM
THROMBOSIS / LABORATORY
STARTING AND STOPPING DOACS
Chair/Organizer: Arthur Allen, Pall Onunderson
Sheraton Ballroom 1


8:00
22

PLANNED INTERRUPTION OF DOAC THERAPY
James Douketis. McMaster University


8:20
23

EMERGENCY REVERSAL OF DOAC THERAPY: CURRENT EVIDENCE ON BEST APPROACHES
Deb Siegal. McMaster University


8:40
24

LABORATORY SUPPORT FOR PATIENTS ON DOAC THERAPY: CHALLENGES TO CHECKING FOR DRUG AND MEASURING LEVELS
Adam Cuker. University of Pennsylvania

9:00 - 10:00 AM
SHORT TALKS
SHORT TALKS 5
Chicago Ballroom 10


SHORT TALKS 6
Chicago Ballroom 9


SHORT TALKS 7
Chicago Ballroom 7


SHORT TALKS 8
Chicago Ballroom 6

10:00 - 10:45 AM
POSTER SESSION
POSTERS/EXHIBITS
Exhibit Hall - Riverwalk AB

10:45 - 12:00 PM
PLENARY SESSION
PLENARY SESSION 2
Chair/Organizer: Peter Kouides, Christine Guelcher
Sheraton Ballroom


10:45
31

ANTICOAGULANT TARGETS: OVERVIEW OF CURRENT AND EMERGING THERAPIES
Jeff Weitz. McMaster University


11:10
32

THE IMPORTANCE OF PATIENT SAFETY CONSIDERATIONS: ANTICOAGULANTS PLACE IN THE PUBLIC HEALTH APPROACH TO MEDICATION SAFETY
Dan Budnitiz. Centers for Disease Control and Prevention


11:35
33

MINIMIZING THROMBOTIC AND BLEEDING COMPLICATIONS IN THE SETTING OF SURGERY
PJ Devereaux. McMaster University

12:15 - 1:45 PM
SATELLITE SYMPOSIUM
CSL BEHRING CORPORATE LUNCH SYMPOSIA
Chicago Ballroom 6


NOVO NORDISK CORPORATE LUNCH SYMPOSIA
Chicago Ballroom 7

2:00 - 3:30 PM
THROMBOSIS
DTI USE
Chair/Organizer: Luis Meillon, Teresa Bordeaux
Sheraton Ballroom 1


2:00
34

DTI USE FOR ATYPICAL VTE (SPLANCHNIC BED, CEREBRAL VEIN THROMBOSIS) AND FOR HIT(T)
Rachel Rosovsky. Massachusetts General Hospital


2:30
35

DTI USE IN LVADS, ECMO, CARDIAC CATH
Jerrold Levy. Duke University School of Medicine


3:00
36

DTI USE IN PEDIATRICS
Shannon Carpenter. Children's Mercy Hospital

2:00 - 3:30 PM
HEMOSTASIS
EMERGING ISSUES IN BLEEDING DISORDERS
Chair/Organizer: Michelle Witkop, Shannon Jackson
Sheraton Ballroom 5


2:00
37

GENETIC TESTING FOR CONGENITAL THROMBOCYTOPENIA SYNDROMES
Brian Branchford. University of Colorado School of Medicine and Children's Hospital Colorado


2:30
38

TREATING PAIN IN PATIENTS WITH BLEEDING DISORDERS
Tyler Buckner. University of Colorado School of Medicine


3:00
39

ANTICOAGULATION FOR PATIENTS WITH BLEEDING DISORDERS (COVERS VTE PROPHY IN ORTHO PROCEDURES, RX OF AF, CAD IN BLEEDING DISORDER PTS AND PVT IN CIRRHOTICS)
Craig Kessler.

2:00 - 3:30 PM
LABORATORY / BASIC SCIENCE
UPDATE ON THROMBOTIC MICROANGIOPATHIES
Chair/Organizer: Charles Eby, Marian Rollins Raval
Chicago Ballroom 10


2:00
40

OVERVIEW ON THROMBOTIC THROMBOCYTOPENIC PURPURA INCLUDING THE IMPORTANCE OF ADAMTS13 ASSAYS FOR DIAGNOSIS
Sateesh Chonat.


2:30
41

NEW INSIGHTS ON THE CONTRIBUTIONS OF ADAMTS13 AND COMPLEMENT TO TTP PATHOGENESIS FROM EXPERIMENTAL MODELS
X. Long Zheng. The University of Alabama at Birmingham


3:00
42

CLINICAL AND LABORATORY CONSIDERATIONS FOR THE LONG TERM FOLLOWUP AND TREATMENT OF TTP
James George. University of Oklahoma Health Sciences Center

3:30 - 4:15 PM
POSTER SESSION
POSTERS/EXHIBITS
Exhibit Hall - Riverwalk AB

4:15 - 5:45 PM
HEMOSTASIS / LABORATORY
EVALUATING FOR BLEEDING DISORDERS: WHAT TO DO AFTER THE PATIENT WALKS THROUGH YOUR DOOR
Chair/Organizer: Salley Pells, Maria Santaella
Sheraton Ballroom 5


4:15
46

BLEEDING ASSESSMENT: KEY ISSUES FOR PATIENT EVALUATION FOR CLINICAL PRACTICE AND RESEARCH ACROSS THE AGE SPECTRUM.
Sarah O'Brien.


4:45
47

OVERVIEW ON THE LABORATORY ASSESSMENT OF PATIENTS REFERRED FOR BLEEDING PROBLEMS.
Cathy Hayward. McMaster University, Hamilton Regional Laboratory Medicine Program


5:15
48

NURSING PERSPECTIVES ON THE NEEDS OF PATIENTS WITH BLEEDING PROBLEMS, WITH CONSIDERATION OF THEIR QUALITY OF LIFE.
Chris Guelcher. Children's National Hospital

4:15 - 5:45 PM
BASIC SCIENCE
NEW INSIGHTS ON PLATELETS AND THEIR FUNCTIONS
Chair/Organizer: A. Koneti Rao, TBD
Chicago Ballroom 10


4:15
49

PLATELET THIOL ISOMERASES: BENCH TO BEDSIDE
Robert Flaumerhaft.


4:45
50

PLATELET-LEUKOCYTE INTERACTIONS
Matthew Rondina.


5:15
51

DETERMINANTS OF PLATELET HYPERREACTIVITY WITH AGING
Jorge DiPaola.

4:15 - 5:45 PM
THROMBOSIS
RISK AND BENEFITS OF COMBINATION ANTITHROMBOTIC THERAPY IN CAD: WHEN LESS IS MORE
Chair/Organizer: Eric Grabowski, Deborah Siegal
Sheraton Ballroom 1


4:15
43

IS THERE ANY ROLE FOR ASPIRIN IN THE TREATMENT OR PREVENTION OF VENOUS THROMBOSIS?
David Garcia. University of Washington


4:45
44

STABLE CAD AND PERIPHERAL ARTERIAL DISEASE: WHEN SHOULD AN ANTICOAGULANT BE CONSIDERED FOR ADDED PROTECTION
Renato Lopes.


5:15
45

UPDATE ON RESPONSIVENESS TO ANTIPLATELET THERAPY
Alan Michelson. Harvard Medical School

5:45 - 6:30 PM
POSTER SESSION
POSTERS/EXHIBITS
Exhibit Hall - Riverwalk AB

6:30 - 8:30 PM
SATELLITE SYMPOSIUM
GENENTECH CORPORATE DINNER SYMPOSIA
Chicago Ballroom 7


SANOFI GENZYME CORPORATE DINNER SYMPOSIA
Chicago Ballroom 6